Status:
UNKNOWN
Sea Water in Allergic Conjunctivitis
Lead Sponsor:
University of Valencia
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
10-80 years
Brief Summary
Background and purpose: Allergic conjunctivitis has increased alarmingly in recent years. The objectives of the study are: 1) To establish the safety and efficacy of applying eyewashes in spray form a...
Detailed Description
Material and methods: Prospective study. A total of 50 patients will be included. A scale from 0 to +3 will be established to quantify the intensity of the different parameters measured. A total of 8 ...
Eligibility Criteria
Inclusion
- The inclusion criteria were patients with mild or moderate allergic conjunctivitis as detailed in Table I. The minimum to be included in the study was the presence in both eyes of three symptoms and one sign (Table II). Among the symptoms, the presence of itching and two more of the following were essential: redness, tearing, foreign body sensation, rubbing, mucous secretion, and/or palpebral swelling sensation. Among the signs, conjunctival hyperemia, papillae in the palpebral conjunctiva, and/or corneal affectation in the form of dotted keratitis were evaluated.
- Table 1 Degree of conjunctivitis I Mild II Moderate III Severe IV Blinding
- Conjunctiva bulbar: congestion granuloma Conjunctiva tarsal: micropapillae 1mm giant \>1 mm cobblestone Corneal staining : micro macro shield ulcer Limbal affectation: \< 180 degrees \>180 degrees insufficiency limbo/pannus/ vascularization corneal
- Table 2 Signs and symptoms evaluated initially and at each visit
- Symptoms Signs:
- Itching - Conjunctival Hyperemia
- Redness - Pads
- Foreign body sensation - palpebral swelling
- Photophobia
- Eyelid swollen sensation
- Mucous secretions
- Rubbing
- Tears
Exclusion
- blepharitis
- meibomian gland dysfunction syndrome (MGS)
- dry eye disease
- topical eye drug such as cyclosporine, tacrolimus, interferon-alpha, mitomycin
- previous eye surgery
- corneal refractive surgery.
- use of contact lenses
- glaucoma
- pterygium
- ocular pemphigoid
- anti-allergic vaccines
- oral or subcutaneous drugs such as antihistamines, anti-leukotrienes (montelukast), corticoids, immunosuppressants or biological drugs.
- rhinitis and dermatitis
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04695795
Start Date
February 1 2021
End Date
December 1 2022
Last Update
January 5 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.